Pediatrix Medical Group (NYSE:MD) Upgraded by StockNews.com to Buy Rating

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

Other analysts have also recently issued reports about the company. Jefferies Financial Group upped their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Mizuho lifted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. UBS Group boosted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Truist Financial raised their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Stock Down 1.8 %

MD opened at $15.22 on Wednesday. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The company has a market capitalization of $1.31 billion, a P/E ratio of -4.97, a P/E/G ratio of 2.22 and a beta of 1.55. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The firm’s fifty day moving average price is $12.38 and its two-hundred day moving average price is $9.77.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 earnings per share. On average, analysts anticipate that Pediatrix Medical Group will post 1.25 EPS for the current year.

Insiders Place Their Bets

In other news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 26,208 shares of company stock valued at $327,617. 2.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of large investors have recently added to or reduced their stakes in MD. BNP Paribas Financial Markets grew its stake in shares of Pediatrix Medical Group by 79.2% during the 1st quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock worth $419,000 after acquiring an additional 18,438 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in Pediatrix Medical Group by 8.8% during the first quarter. Illinois Municipal Retirement Fund now owns 49,526 shares of the company’s stock worth $497,000 after acquiring an additional 4,013 shares in the last quarter. ProShare Advisors LLC boosted its position in Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock valued at $170,000 after purchasing an additional 1,167 shares during the last quarter. Vanguard Group Inc. grew its stake in Pediatrix Medical Group by 1.6% in the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after purchasing an additional 164,333 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Pediatrix Medical Group by 4.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 87,369 shares of the company’s stock worth $877,000 after purchasing an additional 3,669 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.